PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27491078-4	2016	An individual with CPVT harboring a novel mutation in the type 2 cardiac ryanodine receptor (RyR2) was identified whose persistent ventricular arrhythmias during beta-blockade with nadolol were abolished during flecainide treatment.	Nadolol	181-188	ryanodine receptor 2	Homo sapiens	93-97	
30912151-0	2019	A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.	Nadolol	51-58	ryanodine receptor 2	Homo sapiens	20-24	
30912151-1	2019	We report a 17-year-old boy with a large RYR2 exon 3 deletion who has a severe catecholaminergic polymorphic ventricular tachycardia (CPVT) phenotype characterized by refractoriness to both nadolol and flecainide which has previously not been reported in this subgroup of CPVT patients.	Nadolol	190-197	ryanodine receptor 2	Homo sapiens	41-45